Investigator, Dr. Shambhu Aryal, MD, FCCP, Medical Director, Lung Transplant Program and Director, Inova Sarcoidosis Center, Inova Medical Group discusses the results of the ALARM study, led by the National Institutes of Health (NIH) and published in the “Journal of Heart and Lung Transplantation” that validated the ability of CareDx’s AlloSure ® Lung to detect signs of organ rejection and infection in asymptomatic lung transplant recipients in a real-world, home-based surveillance setting. The study also showed that AlloSure Lung identified episodes of acute rejection and infection that would have been missed using a biopsy strategy alone.
Dr. Shambhu Aryal, MD, FCCP, Medical Director, Lung Transplant Program and Director, Inova Sarcoidosis Center, Inova Medical Group
Dr. Shambhu Aryal, MD is a board certified pulmonary disease and critical care medicine specialist affiliated with Inova Fairfax Hospital. He has over 17 years of experience in the medical field and graduated from Tribhuvan University / Institute of Medicine medical school in 2005. His research interests include sarcoidosis and lung transplantation. He also started and leads the Inova sarcoidosis clinic.
His residency was with MedStar Washington Hospital Center with a training specialty in Internal Medicine. And fellowships with University of Kentucky College of Medicine (training specialty: Pulmonary & Critical Care Medicine) and Duke University School of Medicine (training specialty: Lung and Heart Lung Transplantation).